FLT3 (Fms-like tyrosine kinase 3, also known as FLK2 or CD135) and its cognate ligand FLT3L (FLT3 ligand) form a critical cytokine axis that regulates microglial development, hematopoiesis, and immune cell proliferation. Recent discoveries have revealed that FLT3+ microglia represent a disease-protective microglial state that is reduced in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. This finding has spurred interest in developing FLT3/FLT3L-based therapeutic approaches to enhance microglial neuroprotection and clearance of pathological proteins.
The FLT3/FLT3L axis represents a novel therapeutic target that bridges microglial biology with disease modification. Unlike approaches that broadly suppress neuroinflammation, FLT3L administration appears to promote a specific microglial phenotype with enhanced phagocytic capacity and reduced inflammatory damage.
¶ FLT3 and FLT3L Biology
FLT3 is a class III receptor tyrosine kinase expressed primarily on hematopoietic stem cells, dendritic cells, and a subset of microglia. The receptor belongs to the same family as CSF1R (colony-stimulating factor 1 receptor), KIT, and PDGFR, sharing a similar structure with five immunoglobulin-like domains in the extracellular region.
Structure:
- Extracellular domain: Five immunoglobulin-like domains responsible for ligand binding
- Transmembrane domain: Single pass alpha-helical segment
- Cytoplasmic domain: Contains the kinase domain with a characteristic insert region
Expression Pattern:
- Hematopoietic stem and progenitor cells
- Plasmacytoid dendritic cells
- Microglial subset (~15-20% of total microglia in healthy brain)
- Some neurons (low level expression)
¶ FLT3L Ligand
FLT3L is a type I transmembrane protein that exists in both membrane-bound and soluble forms. The soluble form is generated by proteolytic cleavage or alternative splicing and is the primary circulating ligand.
FLT3L Forms:
- Membrane-bound: Cell surface protein involved in cell-cell signaling
- Soluble: Generated by furin-mediated cleavage, circulates in blood and CSF
- Alternative splicing: Multiple isoforms with different activity profiles
Physiological Functions:
- Hematopoietic stem cell survival and proliferation
- Dendritic cell development and homeostasis
- Microglial development and maintenance
- Lymphocyte development (particularly NK cells)
¶ Receptor-Ligand Interaction
FLT3L binds to FLT3 with high affinity (Kd ~0.5-1 nM), inducing receptor dimerization and autophosphorylation. The interaction triggers multiple downstream signaling cascades that regulate cell survival, proliferation, and differentiation.
flowchart TD
classDef blue fill:#e1f5fe,stroke:#01579b,stroke-width:2px
classDef orange fill:#fff3e0,stroke:#e65100,stroke-width:2px
classDef green fill:#c8e6c9,stroke:#1b5e20,stroke-width:2px
classDef red fill:#ffcdd2,stroke:#b71c1c,stroke-width:2px
A["FLT3L Binding"]:::blue
B["FLT3 Receptor Dimerization"]:::blue
C["Autophosphorylation"]:::orange
D["PI3K/Akt Pathway"]:::green
E["STAT5 Pathway"]:::green
F["MAPK/ERK Pathway"]:::green
G["Microglial Survival"]:::green
H["Phagocytosis Enhancement"]:::green
I["Proliferation"]:::green
J["Disease-Protective Phenotype"]:::green
A --> B
B --> C
C --> D
C --> E
C --> F
D --> G
E --> G
E --> H
F --> I
G --> J
H --> J
I --> J
click A "/proteins/flt3l-protein" "FLT3L Protein"
click D "/mechanisms/pi3k-akt-signaling" "PI3K/Akt Pathway"
click H "/mechanisms/microglial-phagocytosis" "Microglial Phagocytosis"
FLT3 activation recruits PI3K to the activated receptor, leading to PIP2 → PIP3 conversion and Akt phosphorylation. Akt promotes microglial survival and enhances phagocytic capacity through:
- mTORC1 activation: Promotes protein synthesis required for phagocytic machinery
- Bad phosphorylation: Blocks intrinsic apoptotic pathway
- FoxO1/3a nuclear export: Promotes expression of survival genes
Recruitment of STAT5 to activated FLT3 leads to STAT5 phosphorylation, dimerization, and nuclear translocation. STAT5 target genes include:
- Bcl-xL: Anti-apoptotic protein
- c-Myc: Metabolic regulator
- SOCS proteins: Feedback regulators of cytokine signaling
GRB2/SOS recruitment activates RAS, leading to RAF → MEK → ERK cascade activation. This pathway drives:
- Cell proliferation and expansion of FLT3+ microglial population
- Enhanced expression of anti-inflammatory genes
- Synaptic pruning regulation
FLT3 and CSF1R share downstream signaling pathways and can functionally cooperate. This cross-talk has important implications:
- Combined targeting: CSF1R inhibitors (used for microglial depletion) may affect FLT3+ microglia
- Additive effects: Dual FLT3/CSF1R agonism may produce enhanced microglial activation
- Homeostatic balance: FLT3L and CSF1 (CSF1R ligand) balance microglial subpopulations
¶ Discovery and Characterization
Single-cell RNA sequencing studies identified FLT3+ microglia as a distinct microglial subpopulation characterized by:
- Gene expression signature: High expression of FLT3, ApoE, and genes associated with homeostatic function
- Disease-protective properties: Enhanced phagocytosis, reduced inflammatory cytokine production
- Neuroprotective phenotype: Expression of neurotrophic factors and anti-inflammatory mediators
Post-mortem studies of AD brain tissue revealed:
- FLT3+ microglial reduction: ~50% decrease in FLT3+ microglia in AD cortex
- Correlation with pathology: Greater reduction associated with higher amyloid plaque burden
- Heterozygous Flt3l mice: Impaired amyloid clearance, increased plaque load
- Therapeutic restoration: FLT3L administration restored FLT3+ microglial numbers
FLT3+ microglia demonstrate enhanced capacity for amyloid plaque clearance:
- Phagocytic activity: Higher rate of Aβ uptake in vitro
- Lysosomal degradation: More efficient processing of internalized Aβ
- Plaque remodeling: FLT3+ microglia associate with compact, well-demarcated plaques
- In vivo evidence: Flt3l haploinsufficiency leads to increased plaque burden
¶ Parkinson's Disease and Neuroinflammation
FLT3+ microglia also play protective roles in PD models:
- Alpha-synuclein clearance: Enhanced uptake and degradation of alpha-synuclein fibrils
- Inflammatory modulation: Reduced production of pro-inflammatory cytokines (IL-1β, TNF-α)
- Neuroprotection: Improved dopaminergic neuron survival in MPTP models
Recombinant FLT3L protein administration represents the most direct therapeutic approach:
Preclinical Evidence:
- Increased FLT3+ microglia in brain after systemic FLT3L administration
- Enhanced amyloid plaque clearance in 5xFAD and APP/PS1 mice
- Improved cognitive performance in behavioral testing
- Reduced neurofibrillary tangle burden in tau models
Delivery Strategies:
- Subcutaneous injection: Twice weekly administration in mouse models
- Gene therapy: AAV-mediated FLT3L expression for sustained delivery
- Cell therapy: Engineered cells secreting FLT3L
Dosing Considerations:
- CSF1R ligands (M-CSF, IL-34) at high doses cause myeloproliferation; FLT3L is more selective
- Crosses blood-brain barrier (BBB) in limited amounts; optimal dosing balances peripheral and central effects
- Species differences in FLT3L responsiveness between mice and humans
Small molecule FLT3 agonists offer advantages over protein therapeutics:
Advantages:
- Oral bioavailability
- Better CNS penetration (some compounds)
- Lower immunogenicity risk
- Easier manufacturing and storage
Lead Compounds:
- FLT3 agonists in clinical development: Identified from oncology literature and repurposed
- Novel synthetic agonists: Designed for neuroinflammatory indications
Development Challenges:
- Off-target kinase inhibition (FLT3 shares homology with other RTKs)
- Toxicity concerns from oncology experience with FLT3 inhibitors
- Ensuring selectivity for microglial FLT3 vs. hematopoietic FLT3
AAV-mediated FLT3L delivery enables sustained therapeutic protein production:
Vector Design:
- AAV9 or AAVrh10 for CNS transduction
- Neuronal and/or microglial targeting via capsid selection
- Regulated expression systems to control FLT3L levels
Preclinical Results:
- Long-term FLT3L expression in brain (>6 months)
- Increased FLT3+ microglia with therapeutic levels
- Reduced amyloid and tau pathology
- No significant safety signals
Clinical Considerations:
- One-time administration vs. repeated protein dosing
- Irreversibility of gene therapy requires careful patient selection
- Manufacturing and regulatory complexity
Several programs are investigating FLT3/FLT3L in AD:
- Recombinant FLT3L: Phase I/II trials planned for early AD
- Gene therapy: IND-enabling studies for AAV-FLT3L
- Biomarker development: CSF FLT3L as pharmacodynamic marker
FLT3L programs are being evaluated for PD:
- Preclinical studies in alpha-synuclein transgenic models
- Biomarker development for patient selection
- Combination approaches with existing PD therapies
FLT3 signaling appears relevant in ALS models:
- Microglial FLT3+ cells reduced in SOD1 mouse model
- FLT3L administration improved microglial neuroprotective phenotype
- Motor neuron survival enhanced in co-culture systems
FLT3L levels are altered in FTD patients:
- CSF FLT3L as potential biomarker for FTD
- Therapeutic exploration in genetic FTD (GRN, C9orf72 mutations)
¶ Safety and Biomarkers
Preclinical studies suggest FLT3L has a favorable safety profile:
Peripheral Effects:
- Mild splenomegaly (increased hematopoiesis)
- Transient increase in circulating dendritic cells
- No significant cytopenias or immunosuppression
CNS Effects:
- Increased microglia numbers (therapeutic goal)
- No evidence of dysplasia or transformation
- No behavioral abnormalities
Oncology Experience Context:
- FLT3 is well-characterized in AML (acute myeloid leukemia)
- FLT3 inhibitors used in oncology; FLT3 agonists are mechanistically opposite
- Risk of myeloproliferation mitigated by selecting appropriate dose range
Potential biomarkers for FLT3/FLT3L therapy include:
- CSF FLT3L levels: Direct measure of target engagement
- FLT3+ microglia in PET: Tracer development for imaging microglial subpopulations
- Inflammatory cytokines: IL-10, TGF-β as markers of anti-inflammatory phenotype
- Neurofilament light (NfL): Monitor neurodegeneration rate
¶ Proteins and Receptors